SEC Comment Letter 0000000000-23-009172 to Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc.
Date: Aug. 22, 2023 · CIK: 0001649989 · Accession: 0000000000-23-009172
AI Filing Summary & Sentiment
File numbers found in text: 333-273979
Letter
United States securities and exchange commission logo August 22, 2023 Lawrence Kenyon Chief Financial Officer Outlook Therapeutics, Inc. 485 Route 1 South Building F, Suite 320 Iselin, New Jersey 08830 Re:Outlook Therapeutics, Inc. Registration Statement on Form S-3 Filed August 14, 2023 File No. 333-273979 Dear Lawrence Kenyon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney Tygesson, Esq.
Show Raw Text
United States securities and exchange commission logo
August 22, 2023
Lawrence Kenyon
Chief Financial Officer
Outlook Therapeutics, Inc.
485 Route 1 South
Building F, Suite 320
Iselin, New Jersey 08830
Re:Outlook Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 14, 2023
File No. 333-273979
Dear Lawrence Kenyon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Courtney Tygesson, Esq.